JP2024516001A5 - - Google Patents
Info
- Publication number
- JP2024516001A5 JP2024516001A5 JP2023566797A JP2023566797A JP2024516001A5 JP 2024516001 A5 JP2024516001 A5 JP 2024516001A5 JP 2023566797 A JP2023566797 A JP 2023566797A JP 2023566797 A JP2023566797 A JP 2023566797A JP 2024516001 A5 JP2024516001 A5 JP 2024516001A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- subject
- amount
- suspected
- cystatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21171491.0 | 2021-04-30 | ||
| EP21171491 | 2021-04-30 | ||
| PCT/EP2022/061544 WO2022229416A2 (en) | 2021-04-30 | 2022-04-29 | Esm1 marker panels for early detection of sepsis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516001A JP2024516001A (ja) | 2024-04-11 |
| JP2024516001A5 true JP2024516001A5 (https=) | 2025-05-12 |
Family
ID=75746433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566797A Pending JP2024516001A (ja) | 2021-04-30 | 2022-04-29 | 敗血症の早期検出のためのｅｓｍ１マーカーパネル |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240230676A1 (https=) |
| EP (1) | EP4330679A2 (https=) |
| JP (1) | JP2024516001A (https=) |
| CN (1) | CN117597584A (https=) |
| WO (1) | WO2022229416A2 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2816410B1 (fr) * | 2000-11-09 | 2003-04-18 | Pasteur Institut | Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire |
| CA2476597C (en) | 2002-02-28 | 2011-05-17 | Metanomics Gmbh & Co. Kgaa | Mass spectrometry method for analysing mixtures of substances |
| US20090197794A1 (en) | 2005-07-13 | 2009-08-06 | Aird William C | Methods of Diagnosing and Treating an Inflammatory Response |
| AU2006299417A1 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes |
| CN103123359B (zh) | 2007-08-03 | 2015-07-29 | B.R.A.H.M.S有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
| CN103477229B (zh) * | 2011-01-21 | 2016-02-03 | 国家医疗保健研究所 | 用于预测败血症患者中呼吸衰竭、肾衰竭或血小板减少症的风险的方法和试剂盒 |
| RU2016112915A (ru) | 2013-09-05 | 2017-10-09 | Эф-Ай-Оу Корпорейшн | Биомаркеры для раннего выявления критической или угрожающей жизни ответной реакции на заболевание и/или ответной реакции на лечение |
| GB201402293D0 (en) * | 2014-02-11 | 2014-03-26 | Secr Defence | Biomarker signatures for the prediction of onset of sepsis |
| US20160146838A1 (en) * | 2014-11-20 | 2016-05-26 | Jean Ronald Brisard | System and method for ebola detection |
| JP6859334B2 (ja) * | 2015-10-08 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７ |
| WO2018088455A1 (ja) * | 2016-11-10 | 2018-05-17 | 国立大学法人千葉大学 | 敗血症診断薬 |
-
2022
- 2022-04-29 JP JP2023566797A patent/JP2024516001A/ja active Pending
- 2022-04-29 CN CN202280032035.6A patent/CN117597584A/zh active Pending
- 2022-04-29 EP EP22724114.8A patent/EP4330679A2/en active Pending
- 2022-04-29 US US18/558,150 patent/US20240230676A1/en active Pending
- 2022-04-29 WO PCT/EP2022/061544 patent/WO2022229416A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kamath et al. | A model to predict survival in patients with end‐stage liver disease | |
| Lau et al. | Early detection of pulmonary arterial hypertension | |
| Chandarana et al. | Visceral adipose tissue in patients with COVID-19: risk stratification for severity: H. Chandarana et al. | |
| Basu et al. | Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children | |
| Ondruschka et al. | Post-mortem in situ stability of serum markers of cerebral damage and acute phase response | |
| JP2016520192A (ja) | 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法 | |
| CN101568837A (zh) | 用于预测血管事件和诊断急性冠状动脉综合征的方法 | |
| Bering et al. | Bioelectrical Impedance Analysis–Derived Measurements in Chronic Hepatitis C: Clinical Relevance of Fat‐Free Mass and Phase Angle Evaluation | |
| Fung et al. | A biomarker panel for peripheral arterial disease | |
| Wan et al. | Combining serum cystatin C with total bilirubin improves short-term mortality prediction in patients with HBV-related acute-on-chronic liver failure | |
| CN105705652A (zh) | 协助鉴别诊断中风的方法 | |
| Tan et al. | Serum creatinine/cystatin C ratio as a case-finding tool for low handgrip strength in Chinese middle-aged and older adults | |
| Makaryus et al. | Falsely elevated cardiac troponin I levels | |
| Raghavan et al. | Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts | |
| Romano et al. | Diagnostic reliability of the procalcitonin serum marker in septic frail patient | |
| Terlecki et al. | Prognostic value of acid-base balance parameters assessed on admission in peripheral venous blood of patients with myocardial infarction treated with percutaneous coronary intervention | |
| Huang et al. | Clinical significance of the C-reactive protein-to-bilirubin ratio in patients with ulcerative colitis | |
| JP2024516678A5 (https=) | ||
| JP2024516680A5 (https=) | ||
| RU2754776C1 (ru) | Способ клинико-лабораторного прогнозирования тяжести covid-19 | |
| WO2003039349A2 (en) | Method of using physiological markers to estimate cardiovascular risk | |
| JP2024516001A5 (https=) | ||
| JP2024516677A5 (https=) | ||
| JP2024515086A5 (https=) | ||
| JP2024516681A5 (https=) |